The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis
Abstract
Objectives The objective of this study was to evaluate the efficacy and safety of atomoxetine in children and adolescents. Materials and methods We searched for studies published between 1985 and 2006 through Medline, PubMed, PsychInfo and Cochrane Central Register of Controlled Trials (CENTRAL 2006 Issue 3) using keywords related to atomoxetine and attention-deficit/hyperactivity disorder (ADHD) and scanned though reference lists. We included nine randomized placebo-controlled trials (atomoxetine:placebo = 1,150:678). Results Atomoxetine was superior (p Conclusions Atomoxetine is efficacious in reducing ADHD symptoms. It may have a role in treating comorbid ODD or depression, and probably in comorbid anxiety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analysis of seven studies with over 1,600 participants reported that atomoxetine moderately reduced ADHD symptoms.”
From The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder (2021) · cites this paper as Cheng et al., 2007
In the citing paper
“Among nonstimulant medications, 1 selective norepinephrine reuptake inhibitor, atomoxetine,99,100 and 2 selective α-2 adrenergic agonists, extended-release guanfacine101,102 and extended-release clonidine,103 have also demonstrated efficacy in reducing core symptoms among school-aged children and adolescents”
From Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents (2019) · cites this paper as [99]
In the citing paper
“Efficacy of both methylphenidate and atomoxetine has been established in placebo controlled trials [12-15].”
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
(1998) · Cited by 2,026
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.5.564 · Cited by 1,738 · cited 2×
“Oppositional defiant disorder (ODD) is the most common comorbid condition in ADHD, and it affects 30–60% of children with ADHD (Biederman et al. 1991; Goldman et al. 1998; Jensen et al. 2001).”
BackgroundConners' rating scales-revised : technical manual
Conners, C. K. (1997) · Medical Entomology and Zoology · Cited by 1,368
Johnston, C., & Mash, E. J. (2001) · Clinical Child and Family Psychology Review · doi:10.1023/a:1017592030434 · Cited by 1,161 · cited 2×
“2002), family (Johnston and Mash 2001) and social difficulties (Bagwell et al.”
BackgroundBymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123 · cited 3×
“Atomoxetine has a theoretical advantage over methylphenidate because its action spares the striatum and nucleus accumbens (Bymaster et al. 2002) that are affected in substance abuse, particularly in comorbid ODD patients who are at risk of substance abuse (Wilens et al. 2006).”
BackgroundGender Differences in ADHD: A Meta-Analysis and Critical Review
GAUB, M., & CARLSON, C. L. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199708000-00011 · Cited by 1,117 · cited 1×
“The former explanation may be further explained by the relatively less severe externalizing or disruptive behaviours in girls (Biederman et al. 2002; Gaub and Carlson 1997), which upon drug treatment may appear to improve more than boys in the eyes of the instrument raters.”
BackgroundDiagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Goldman, L. S. (1998) · JAMA · doi:10.1001/jama.279.14.1100 · Cited by 1,082
ADHD Comorbidity Findings From the MTA Study: Comparing Comorbid Subgroups
JENSEN, P. S., HINSHAW, S. P., KRAEMER, H. C., LENORA, N., NEWCORN, J. H., ABIKOFF, H. B., MARCH, J. S., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00009 · Cited by 974 · cited 1×
“Oppositional defiant disorder (ODD) is the most common comorbid condition in ADHD, and it affects 30–60% of children with ADHD (Biederman et al. 1991; Goldman et al. 1998; Jensen et al. 2001).”
Background
Research works printed but not linked: 3
- DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998) ADHD rating scale-IV: checklists, norms, and cinical interpretations. Guilford, New York
- Landgraf JM, Abetz L, Ware JE (1996) The CHQ user’s manual, 1st edn. The Health Institute, New England Medical Center, Boston
- Tannock R, Schachar R (1992) Is ADHD with comorbid overanxious disorder different from ADHD? In: Comorbidity of ADHD: discriminating features and methodologic problems, Newcorn J (chair). Symposium conducted at the 39th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC
Cited by
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., et al. (2019) · Pediatrics · doi:10.1542/peds.2019-2528 · Cited by 1,562
“140 Authors of other reports suggest that more than 90% of patients will have a bene fi cial response to 1 of the psychostimulants if a range of medications from both the methylphenidate and amphetamine and/or dextroamphetamine classes”
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.022 · Cited by 1,545
“(Cheng et al., 2007).”
Wehmeier, P. M., Schacht, A., & Barkley, R. A. (2010) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2009.09.009 · Cited by 628
The quality of life of children with attention deficit/hyperactivity disorder: a systematic review
Danckaerts, M., Sonuga-Barke, E. J. S., Banaschewski, T., Buitelaar, J., Döpfner, M., Hollis, C., Santosh, P., Rothenberger, A., Sergeant, J., Steinhausen, H.-C., et al. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0046-3 · Cited by 516
“Cheng et al. [ 16 ] Meta-regression analysis of RCTs (ATX vs. Placebo) CHQ Parent 1828 ADHD NA Parent reported QoL improved with ATX treatment”
MethodInfluential
Metadata
- Authors
- Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L.
- Affiliations
- Queen Mary Hospital (CN)
- Corresponding author
- Cheng, Jackie Y. W.
- Venue
- Psychopharmacology
- Published
- 2007-06-16
- Volume
- 194
- Issue
- 2
- Pages
- 197-209
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1996091936
- Semantic Scholar
- d3e56ca1002c942102f6379b25486106538675bd
- Cited by
- 185
- References
- 64
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 3 · 2017: 10 · 2016: 7 · 2015: 11 · 2014: 13 · 2013: 21 · 2012: 18
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- atomoxetine, attention deficit hyperactivity disorder, children and adolescents, ADHD symptom reduction, relapse prevention, adverse events, gastrointestinal adverse effects, oppositional defiant disorder, hyperactive-impulsive subtype, inattentive subtype, quality of life, predictors of treatment response, predictors of adverse events, number needed to treat, number needed to harm, stimulant medication
- MeSH terms
- Atomoxetine Hydrochloride, Adolescent, Attention Deficit Disorder with Hyperactivity, Child, Female, Humans, Male, Propylamines, Quality of Life, Regression Analysis, Sex Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Adrenergic Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. https://app.cochat.ai/papers/10.1007/s00213-007-0840-x
- The paper
- Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007). Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology. https://doi.org/10.1007/s00213-007-0840-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.